Conversely, intermediate muscular dystrophy has been used to describe “mildly affected” DMD patients (those whose genetic structure would predict prematurely truncated dystrophin and loss of ambulation by 12 years of age) or “severely affected” BMD cases (those who would be expected to produce some functional dystrophin and therefore remain ambulant after 16 years of age). This evidence concerns the gene DMD and Duchenne muscular dystrophy.